NCT06214091

Brief Summary

Acute severe ischemic stroke is a life-threatening subtype of stroke. Due to stress ulcer and gastric reflux in acute stage, patients with severe ischemic stroke are always complicated with stomach bleeding and pulmonary infections, resulting in poor prognosis and even death. Reducing stomach acidity and avoiding gastric reflux play a pivotal role on controlling serious complications after austere ischemic attack. Gastrointestinal decompression is an cheap, safe, effective and acknowledgemented strategy for treating stomach bleeding and preventing gastric reflux in clinical settings. Early gastrointestinal decompression seems to be an available method to reduce stomach acidity and avoid gastric reflux after severe ischemic stroke. Therefore, we aimed to evaluate the safety and efficacy of early gastrointestinal decompression in patients with acute severe ischemic stroke.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P50-P75 for not_applicable stroke

Timeline
Completed

Started Feb 2024

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 10, 2024

Completed
9 days until next milestone

First Posted

Study publicly available on registry

January 19, 2024

Completed
13 days until next milestone

Study Start

First participant enrolled

February 1, 2024

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2025

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2025

Completed
Last Updated

January 22, 2024

Status Verified

January 1, 2024

Enrollment Period

1 year

First QC Date

January 10, 2024

Last Update Submit

January 18, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • 90-day Death

    Death rate at 90 days

    90 days

Secondary Outcomes (4)

  • 90-day mRS

    90 days

  • 90-day Barthel scores

    90 days

  • 30-day mRS

    30 days

  • 30-day Barthel scores

    30 days

Study Arms (2)

Gastrointestinal decompression group

EXPERIMENTAL
Procedure: Gastrointestinal decompression

Control group

PLACEBO COMPARATOR
Procedure: Control

Interventions

Gastric tube is inserted within 24-hour severe ischemic stroke attack; gastrointestinal decompression is performed for 48 hours.

Gastrointestinal decompression group
ControlPROCEDURE

Gastric tube is inserted within 24-hour severe ischemic stroke attack.

Control group

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age 18-80 years
  • severe AIS, including NIHSS score\>20 in dominant hemisphere infarction, or NIHSS score\>15 in non-dominant hemisphere infarction, or NIHSS consciousness score \>1; · massive infarction, characterized by infarction area larger than 1/3 of the effected middle cerebral artery territory and/or the cerebellum territory presented in admitted computed tomography (CT) or MRI
  • onset-to-needle time within 24 hours
  • prestroke modified Ranking scales (mRS)≤1
  • sign the informed consent.

You may not qualify if:

  • Recent respiratory infection and/or gastrointestinal bleeding
  • austere diseases such as tumors and dyscrasia
  • intention to undergo emergency thrombectomy
  • pregnant women or nursing mother
  • contraindication for gastric tubes
  • participating in other clinical trials within previous 3 months.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Stroke

Condition Hierarchy (Ancestors)

Cerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular Diseases

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principle investigator

Study Record Dates

First Submitted

January 10, 2024

First Posted

January 19, 2024

Study Start

February 1, 2024

Primary Completion

February 1, 2025

Study Completion

July 1, 2025

Last Updated

January 22, 2024

Record last verified: 2024-01